So excited that our work lead by @jieliu09 was featured in Best of ASH!! Huge shout out to the lab and our collaborators on this! @pnatarajanmd @AlexBickMDPhD @Link1Daniel @yincaoScD Ken Offit and Zsofia Stadler among others. Thanks to @MDSFoundation for funding the work.

Goodbye San Diego. Had an amazing time at my first @ASH_hematology Annual Conference! Already looking forward to #ASH24 😊 @KellyLBolton @WUHemeOncFellow

In case you were wondering…they nailed it! Celebrating two oral and two poster presentations from a very talented bunch. Special congrats to @jieliu09 and @Scott_Beeler for their abstract achievement awards. Couldn’t ask for a better team and environment @WashUOnc @WashUHeme

Congratulations to my outstanding future @WUHemeOncFellow co-fellow @AlexaLoncharich on winning an #ASH23 Abstract Achievement Award for her work on prediction of bleeding risk on AC in cancer-associated VTE! @KSanfilippoMD @WUHemeOncFellow @WashUHeme @WashUIMRes

Outstanding @WashUIMRes resident and future @MDAndersonNews heme-onc fellow Nikhil Grandhi presenting his work at #ASH23 showing that GLP-1 agonist therapy is associated with reduced risk of progression of MGUS to MM in white, but not black VA patients.

Outstanding #ASH23 oral presentation by @jieliu09 on the role of germline variants in CH initiation and progression to hematological malignancy! @KellyLBolton @WashUOnc @WUSTLdbbs

Accurate risk stratification of CH is needed to define patients for intervention. How might we improve this? We think both germline genetics and proteomics. Come learn why with two talks from our lab by @jieliu09 at 2:45 PM and @Scott_Beeler at 5:15 PM in SDCC Room 24 at #ASH23

Current @WashUIMRes resident and future @MDAndersonNews heme-onc fellow Nikhil Grandhi making connections already! #ASH23

Great presentation by Armin Ghobadi from @WashUOnc at #ASH23 on WU-CART-001, a phase 1/2 study of an allogenic anti-CD7 CAR T cell therapy in R/R T-ALL/LBL. Encouraging activity (ORR 78% & CR 67%) with manageable toxicity. Potential bridge to allo SCT. @SitemanCenter

Stellar @WashUIMRes resident Kelsey Bria presenting her work with @KSanfilippoMD at #ASH23 on high risk PE outcomes by time to starting anticoagulation (AC). They found worse survival with delayed initiation of AC similar to antibiotics in sepsis. @WUHemeOncFellow @WashUHeme

Final #ASH23 Plenary is on dose optimization of hydroxyurea in sickle cell disease in Africa. The phase 1/2 open label trial showed that HU dose optimization is feasible, safe, and improves outcomes including pain + acute chest (vs fixed dose HU).

Fifth #ASH23 Plenary is on the effects of prenatal folate status on hematopoiesis in offspring. Prenatal folate induces persistent hematopoietic changes into adulthood through metabolic reprogramming of HSCs.

Fourth #ASH23 Plenary is on IsKia, a phase 3 trial of KRd +/- isatuximab (anti-CD38) as pre-transplant induction therapy in newly diagnosed multiple myeloma. Isa-KRD had higher rates of MRD negativity at all time points and subgroups assessed; PFS + OS are pending.

Next #ASH Plenary is on SF3B1 splicing from Salima Benbarche of @AbdelWahablab. They identify GPATCH8 as a novel RNA splicing factor required for mis-splicing induced by mutant SF3B1. Targeting GPATCH8 in SF3B1 mouse models rescued defective hematopoiesis.

Second #ASH23 Plenary is on dWIZ, an oral small molecule molecular glue degrader of WIZ. Degradation of WIZ induces increased expression of fetal hemoglobin. dWIZ was well tolerated in primate models and plans are underway to study it in humans with sickle cell disease.

First #ASH23 Plenary is on AGAVE-201, a phase 2 study of axatilimab (anti-CSF-1R) in chronic GVHD s/p multiple prior lines of therapy. Impressive response rates were observed (74% ORR) and interestingly best with the lowest dose tested.

Very excited to share our work on the role of proteomics in myeloid neoplasm risk prediction using the @uk_biobank at #ASH23 tomorrow (12/11) at 5:15 PM in SDCC Room 24. Thank you @KellyLBolton for your exceptional mentorship! @WUHemeOncFellow @WashUIMRes

Feeling the excitement of 🎅 Christmas mornings🎄from childhood, as I get ready to attend my first @ASH_hematology Annual Meeting today! #ASH23 @WUHemeOncFellow @WashUIMRes

I am incredibly grateful for the support from my family, friends, and mentors each step of the way. @WashUIMRes @VanderbiltMSTP @KellyLBolton @RenalRhapsody

Thrilled to share that I matched at WashU for Heme/Onc fellowship! I am so excited to start the next step in my career at such an outstanding program. @WUHemeOncFellow @WashUHeme @WashUOnc @WUDeptMedicine @SitemanCenter @SaiamaWaqar @SaiamaWaqar